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maging technologies have improved sensitivity/specificity to detect metastatic lesions before symptoms arise. Considering the progress made
n the treatment of metastatic disease and the rapid evolution of targeted therapy, that requires customization of the strategy according to
olecular characteristics of the disease, patients could derive real benefit to early detection of disease recurrence. This hypothesis must be
ested in a prospective clinical trial.
 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-SA license
http://creativecommons.org/licenses/by-nc-sa/3.0/).
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.  Introduction  and  terminology
The overall prevalence of women living with a diagno-
is of breast cancer (BC) is increasing in the industrialized
ountries [1], thus management of breast cancer survivors
epresents a daily practice problem for both oncologists and
rimary care physicians (PCP).
After a radical primary treatment, patients with early stage
ancer enter in a structured surveillance phase usually called
cancer follow-up” [2]. According to the Cochrane Breast
ancer Group, terms such as “routine testing”, “follow-
p” or “surveillance” indicate the regular use of laboratory
r instrumental tests in otherwise asymptomatic patients
o detect distant metastases earlier [3]. This definition is
rimarily focused on early detection of disease recurrence
n patients otherwise asymptomatic. However, considering
hat worldwide population is aging and 50–70% of BC
urvivors experience persistent impairment or limitations
fter primary treatment [4,5], physicians also have to deal
ith co-morbidities and long-term side effects of treatment
uch as anthracycline-related cardiac damage, anti-estrogen-
ssociated bone disease, chemotherapy-induced infertility,
nd risk of second malignancies. Supportive and psychologi-
al interventions should be an important part of the oncologist
ole. This more comprehensive activity is usually termed as
survivorship care”.
Given the required large amount of resources and the pos-
ible important consequences in terms of patients’ health and
urvival, several prospective studies were conducted with the
im of defining the best follow-up strategy in BC survivors
6–11] and clinical guidelines are constantly updated [12,13].
 survival benefit derived from the early detection of disease
ecurrence was rarely demonstrated in the general popula-
ion, although several other needs of cancer patients were
ointed out, leading to a wider understanding of surveillance
nd to a shift toward survivorship care. Unfortunately, while
ncological research is actively pushed in the field of pharma-
ological therapy, little has done to solve the many questions
hat still are open in survivorship care.
.  Surveillance.1.  Summary  of  literature  review  and  current  guidelines
Data on BC follow-up date back to the 1990, when results
rom two randomized trials were published: the GIVIO
p
bGruppo Interdisciplinare Valutazione Interventi in Oncolo-
ia, Interdisciplinary Group for Cancer Care Evaluation) trial
6] and the Rosselli del Turco trial [7]. They comparatively
valuated conventional follow-up based on regular physical
xaminations and annual mammography with more inten-
ive investigations, such as chest X-rays, bone scan, liver
ltrasound (US), and laboratory tests for tumor markers in
rder to search for distant metastases. Both trials showed no
verall survival (OS) benefit arising from intensive follow-up
s compared with conventional follow-up [8,9]. In particu-
ar, the first analysis of the Rosselli Del Turco trial showed
n uncertain survival benefit arising from intensive follow-
p compared with conventional follow-up, but the data was
ot confirmed after 10-year follow-up. The 10-year mortality
umulative rates were 31.5% for the conventional follow-
p and 34.8% for the intensive ones (hazard ratio 1.05;
5% Confidence Interval (CI) 0.87–1.26) [8]. Similarly, the
IVIO at a median follow-up of 71 months, showed no
ifferences in survival, with 132 deaths (20%) in the inten-
ive group and 122 deaths (18%) in the control group (odds
atio = 1.12; 95% CI = 0.87–1.43). Moreover, the GIVIO trial
ssessed a decreased health-related Quality-of-life (QoL)
n the intensive-screening group [6]. Recently, a Cochrane
eview involving more than 2500 women, confirmed that
ntensive follow-up did not improve OS and disease-free sur-
ival (DFS). These results were consistent among subgroup
nalyses according to patient age, tumor size and lymph node
tatus before primary treatment [3].
Other important issues concern frequency and location of
ollow-up visits. In 1997 a single center trial showed that
nnual follow-up visits after mammography did not increase
he use of local practitioner services or telephone triage com-
ared with visits scheduled every 3–6 months. However, due
o the small sample size of this trial, definitive conclusions
bout effectiveness and cost-effectiveness of routine follow-
p with respect to disease outcomes were not assessable [9].
n 1996 and 2006, two multicenter, randomized, controlled
rials showed no differences in terms of recurrence-related
linical events rate and health-related QoL between follow-up
erformed by a medical oncologist or by a PCP [10,11]. How-
ver, median follow-up of both trials was short (18 months
nd 3.5 years, respectively) and studies were underpowered
o evaluate the impact on OS.To date, the ASCO [12] and the NCCN (National Com-
rehensive Cancer Network) [14] guidelines recommend
reast self-examination, annual bilateral mammography and
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eriodic history and physical examination (every 3–6 months
or the first 3 years, then every 6–12 months for 2 years
r every 4–6 months for 5 years, respectively, then every
2 months). They also underline the importance of coun-
eling about symptoms of recurrence and active lifestyle.
oreover, they recommend periodic pelvic examinations for
very woman, in particular patients taking tamoxifen, who
re at increased risk of endometrial cancer, and bone mineral
ensity determination for women undergoing an aromatase
nhibitor or who experience ovarian failure secondary to treat-
ent. Physicians should assess and encourage adherence to
djuvant endocrine therapy, and women at high risk for famil-
al breast cancer syndromes should be referred for genetic
ounseling.
In asymptomatic patients, there are no data to indicate that
ther laboratory or imaging tests (e.g. blood counts, routine
hemistry tests, chest X-rays, bone scans, liver US exams,
omputed tomography (CT) scans, positron emission tomo-
raphy (PET) scans or any tumor markers such as CA15-3 or
EA) can produce a survival benefit.
The ESMO guidelines [15] focus attention to survivorship
are, highlighting that the purposes of follow-up are also to
valuate and to treat therapy-related complications (such as
enopausal symptoms, osteoporosis and second cancers) and
o provide psychological support and information in order to
nhance returning to normal life after BC. Table 1 summa-
izes current guidelines on breast cancer follow-up.
Currently, no specific trials were conducted to evaluate
he best follow-up strategy in particular population, such as
ale BC, elderly patients, very young patients, and BRCA1-2
utation carriers.
.2.  Uses  and  abuses  of  resources
In clinical practice intensive follow-up is a widespread
eality and it costs 2.2–3.6 times more than guidelines-
ompliant follow-up [16], as a result of non-mammographic
ests performed in the absence of any warning signs or symp-
oms of recurrence [17]. The ASCO included BC surveillance
n the top-five list of oncological practices that could be
mproved and simplified in order to reduce costs [18].
The higher-than-recommended intensity involves both
linical examinations and imaging. A Canadian population-
ased analysis showed that the mean number of visits in
he first 5 years after primary treatment was usually higher
han recommended by the ASCO guidelines. For example,
uring the second year patients underwent a mean of 11.2
isits by different physicians, including PCP, medical oncolo-
ist, radiation oncologist, surgeon and others, compared with
–4 visits recommended [19]. These numbers are a common
esult of a widespread duplication of care.
In line with these results, Keating and Colleagues observed
hat 13.3% of the 37,967 patients collected in the Surveil-
ance, Epidemiology, and End Results (SEER) – Medicare
atabase had at least one bone scan, 29.2% had a tumor anti-
en test, 10.9% had chest/abdominal imaging, and 58.8%
•gy/Hematology 91 (2014) 130–141
ad a chest X-ray in the first year of follow-up, and patients
ollowed by medical and radiation oncologists had the highest
hance of undergoing non-recommended tests [20]. Simi-
arly, a National survey conducted among Italian medical
ncologists showed an abuse of imaging and tumor markers
est in asymptomatic BC survivors [21].
There are multiple possible reasons of overuse of imag-
ng and laboratory testing. The first one is the patient-driven
nxiety and the feeling of reassurance induced by examina-
ions. Patients are prone to associate the frequency of clinical
xaminations and testing with improved outcomes [22] due
o the unrealistic belief that more testing could anticipate the
iagnosis of recurrence and improve treatment outcomes. A
econd issue to be taken into account is the dearth of prospec-
ive trials with new generation imaging (CT and PET scans)
r oriented to special populations (for example women under
0 years old or patients with triple-negative or HER2-positive
isease). Finally, an important trigger of unnecessary exami-
ations and visits may be the absence of a clear coordination
mong all the professionals involved in the survivorship plan
23]. By contrast, uncoordinated care can also be the cause
f underuse of appropriate visits and tests: the SEER data
20] showed that in United States only 27% of breast can-
er survivors’ aged 65 years or older saw their oncologists
nnually for 3 years after active treatment and a case control
tudy conducted in Ontario [24] highlighted that among BC
urvivors only a minority underwent colorectal and cervical
ancer screening, despite being seen by multiple specialists
uring the first 5 years after primary treatment. These exam-
les of lower-than-standard practice support the hypothesis
hat resources may not be equally distributed among surviv-
ng patients.
.  Advances  in  management
.1.  Advances  in  biology
A huge amount of evidence suggests that the risk of BC
ecurrence and death is influenced not only by stage at initial
resentation but also by the underlying biology of the tumor
25]. Overall, the hazard rate varies over time according to
redictive and prognostic factors [25]. A better understand-
ng of patterns of recurrence is an important medical driver
or both the treatment and the surveillance clinician decision
rocess.
Currently, BC is classified into five different molecular
ubtypes [26–28] according to immunohistochemical (IHC)
lassification:
 Luminal A (characterized by hormone receptors (HR)-
positive tumor cells and low Ki-67 expression; human
epithelial growth factor receptor 2 (HER2)-negative status)
 Luminal B (HR-positive cells and high Ki-67 expression;
HER2-negative status)
 Luminal/HER2 (HR-positive cells and HER2-positive sta-
tus)
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Table 1
Summary of current guidelines on breast cancer follow-up.
Scientific society History and
physical
examination
Mammography Breast
self-examination
Intensive
follow-up
Bone mineral
density
Gynecologic
assessment
ESMO 2011 [15] Not specified Every 12 months Not specified Not recommended Not specified Not specified
ASCO Update
2013 [6]
Every 3–6 months
for the first 3
years, every 6–12
months for the
next 2 years, then
annually
Every 12 months Monthly Not recommended Not specified All women
NCCN Version
3.2013 [14]
Every 4–6 months
for 5 years, then
annually
Every 12 months Not specified Not recommended Women on
aromatase
inhibitor or who
experience ovarian
failure secondary
to treatment
Women on
tamoxifen: every
12 months
AIOM 2013 [126] Every 3–6 months
for 5 years, then
Every 12 months Not specified Not recommended If clinically
indicated
Women on
tamoxifen: if
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 HER2 enriched (HR-negative and HER2-positive status)
 Triple negative (HR-negative and HER2-negative status)
The hazard rates for relapse among HR-negative and/or
on-luminal A tumors show a sharp peak soon after initial
iagnosis. Conversely, hazard rates for HR-positive and lumi-
al A tumors are persisting low over the time [25]. A recent
nalysis showed that patients with Luminal B breast cancer
ad a continuously higher hazard of breast cancer recurrence
ver time and a shorter OS compared with Luminal A patients
29,30]. Moreover, Luminal B patients had higher rates of
one as first recurrence site than other subtypes. Visceral
ecurrence as first event was similar among Luminal B, HER2
nriched and triple negative BC.
From a biological point of view, the observation of dif-
erent patterns of relapse suggests different mechanisms
nvolved in early and late BC events. As a consequence,
t is tempting to hypothesize that schedule and intensity of
urveillance should vary accordingly.
.2.  Advances  in  surveillance  strategies
.2.1.  Locoregional  recurrence
The survival of women suffering locoregional recurrence
s markedly different compared to those suffering distant
etastases (80% 5-year relative survival rate versus 25% 5-
ear relative survival rate, respectively) [31] and patients with
solated locoregional or contralateral breast cancer recurr-
nces detected without symptoms have a better survival
ompared to patients in whom a late symptomatic detection
s performed. Over the last two decades, it has been demon-
trated that patients with solitary first locoregional recurrence
fter mastectomy may achieve a 5-year DFS rate of 61–79%
f they underwent a radical locoregional treatment combined
ith systemic adjuvant therapy [32,33].
a
pclinically
indicated
Unfortunately, the first site of relapse is represented by
ocal recurrence in only one-third of recurrent BC patients
34]. Even if some retrospective analyses suggested that hav-
ng an inflammatory BC at the primary diagnosis [35] as
ell as the tumor stage and pathological nodal stage after
eoadjuvant treatment [36] may predict for a higher risk
f locoregional recurrence, no strategy are current avail-
ble to identify patients who are more likely to have a local
elapse.
The detection of isolated locoregional and contralateral
ecurrence or new breast primary in asymptomatic patients
y mammography leads to an absolute reduction in mortality
f 17–28% [37]. Nevertheless, surveillance mammography
s affected by both false-negative (approximately 10% of
alpable tumors are not clearly visible on mammography)
nd false-positive results, which require further investiga-
ions, especially when deleterious changes in breast tissue
ave been induced by surgery and radiotherapy [38–40]. In
uch cases, the reliability of the diagnosis might be improved
y the use of US or magnetic resonance imaging (MRI)
41–43]. In particular, MRI of the breast can be used as a
roblem-solving tool in the evaluation of patients in whom
quivocal abnormalities are identified by mammography or
hysical examination [44,45]. MRI is particularly appealing
or surveillance of young women due to its proven higher
ensitivity compared to mammography, especially in dense
reasts [46–50]. However, due to the relatively low specificity
f MRI for BC recurrence (range from 66 to 100%) [51–58]
nd the current high cost of this technique [59], MRI could
ot be considered a recommendable tool in BC follow-up.
oreover, a recent study showed that MRI did not reduce the
isk of both local and distant disease relapse [60].
For these reasons mammography is the cornerstone of
ppropriate BC follow-up after primary treatment for all
atients [12].
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an early intramedullary malignant lesion before there is any
cortical destruction or reactive processes. MRI was shown34 F. Puglisi et al. / Critical Reviews in
.2.2.  Distant  metastases
In the early 1990s it has been reported that a small percent-
ge of metastatic breast cancer (MBC) patients who achieved
 complete remission after systemic treatment remained
isease-free over 20 years. Overall, these long-survivors
epresented only 1–3% of all metastatic patients, but they
hallenged a paradigm: MBC was no longer always a fatal
ondition [61,62].
Looking into the patient and tumor characteristics of the
ong-survivors we realized that they shared some important
eatures: they were young, with good performance status and
ith a limited burden of metastatic disease [63,64]. In par-
icular, having an oligometastatic disease seemed to be the
trongest predictor for long survival.
Over the last three decades, several studies confirmed this
ssumption. The implementation of multidisciplinary aggres-
ive approach in patients with a single metastatic lesion has
ead to a disease-free interval longer than 15 years [65–69],
nd a retrospective analysis of patients with 1 or 2 metastatic
ites showed a complete response with systemic treatment of
8% and a 20-year OS rate of 53% [62].
These impressive results can be related with both an
mprovement in treatment for MBC and an improvement in
arly detection of metastatic disease limited to 1–2 sites.
However, more than 20% of patients have a multiple sites
isease at presentation of metastatic spread [70]. According
o a recent retrospective analysis, the most common sites of
istant recurrence were bone (41.1%), lung (22.4%), liver
7.3%), and brain (7.3%) [62]. Interestingly, different patient
nd tumor characteristics underlined different patterns of
istant relapse: bone metastases were more likely to be diag-
osed in patients with HR-positive disease, lung and liver
etastases in patients with a more advanced stage at the time
f primary diagnosis, and brain metastases in patients with
R-negative disease [29,62]. The worse survival outcome
ver the initial years after diagnosis was observed in triple
egative BC patients and in patients with HER2-positive dis-
ase who did not received any anti-HER2 treatment [29].
oreover, even if the introduction of drugs targeting the
ER2 has led to an impressive improvement in both DFS
nd OS [71–74], data from the first trial with trastuzumab
n metastatic setting showed that patients who received the
nti-HER2 treatment upfront had a survival advantage com-
ared with who received it after progression [70]. These
ndings suggest that an early diagnosis and treatment of
ER2-positive disease recurrence may improve outcome of
hese patients.
Diagnostic tools currently used in the surveillance, such
s PET, MRI, and CT, have a wide range of accuracy in the
etection of all the sites of relapse [75]; consequently it is not
ikely to assume a one shot diagnostic examination that can be
ppropriately used for the surveillance of distant relapse but
ather this surveillance is likely to comprise a combination
f these technologies. The poor prognosis of patients with
istant relapse justify a strong effort to identify a “systemic
urveillance strategy” effective in improving outcome.
t
dgy/Hematology 91 (2014) 130–141
.2.2.1.  Conventional  workup.  Conventional imaging tests
CITs) available to detect distant metastases include con-
entional X-rays, CT scan, US, bone scan and, in a limited
umber of settings, MRI. Diagnostic accuracy of CITs in
urveillance setting of BC survivors is mainly extrapolated
rom studies comparing conventional workup and PET scan
nd they are far to be completely assessed [40]. For example,
T scan is widely used in clinical practice but diagnos-
ic accuracy of CT imaging in detecting recurrent and/or
BC, ranges from 40 to 92% in sensitivity and from 41 to
00% in specificity [76–79]. Moreover, abdominal US has
he undoubted advantage of minor economical and biological
osts but its use in BC is not supported by adequate scien-
ific evidences; most of the studies assessed the diagnostic
ccuracy of US in the diagnosis of local recurrence and not
f liver metastases [41].
A particular mention should be made for the bone involve-
ent. Bone is the most common site of distant metastases
rom BC [80]; complications resulting from bone metastases
nclude hypercalcemia, bone pain, pathological fractures, and
pinal cord compression [81]. Early detection of metastatic
isease may prevent skeletal complications, offer a better
hance to control the disease process, and improve patients’
oL [82].
From a recent review, emerged that the absence of risk
tratification in published data does not adequately eval-
ate the benefit of intensive surveillance among patients
ith known high-risk disease, therefore to plan studies for
ssessing an accurate surveillance strategy in aggressive
umors is a real need [83].
Conventional X-ray has a low sensitivity in detection of
one metastases. It has been estimated that a 30–75% reduc-
ion in bone density is required to visualize a metastasis on
adiographs. In the same way, a considerable cortical destruc-
ion is required for visualization of a metastasis by CT scan;
ensitivity and specificity of this modality in detecting early
alignant bone involvement [84,85] are relatively low. Bone
can offers a relatively sensitive and reasonably priced eval-
ation of the whole skeleton in a single imaging examination
ut it is affected by a poor anatomic resolution [86] that
ay results in not-detecting lytic lesions or difficulty in dis-
inguishing tumor from degenerative/traumatic events. The
etection rate of bone metastases by bone scan in patients
ith early-stage BC is very low (0.82 and 2.55% in stage I
nd II, respectively), but it increases to 17% in patients with
tage III disease. Therefore, bone scan should be performed
n symptomatic patients, when there is a clinical suspicion
or metastatic bone involvement [87], and in advanced-stage
isease.
Considering that MRI has high soft tissue contrast, and
ood spatial and contrast resolution, it is an optimal imag-
ng modality for bone marrow assessment. MRI can detecto be better than PET, CT, and bone scan for bone marrow
isease [88].
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.2.2.2.  PET  and  PET/CT  scanning.  The diagnostic poten-
ial of whole-body 18-fluoro-2-deoxy-d-glucose (FDG)-PET
an be considered in patients with high risk of recurrence
89,90]. Moreover, the advantages of FDG-PET/CT in iden-
ifying locoregional recurrence are the high sensitivity and
he ability to differentiate post-surgical/radiotherapy changes
rom true recurrence. An important role of FDG-PET seems
o be the detection of distant metastases in patients with sus-
ected recurrence disease, e.g. when biochemical markers
CA15.3 or CEA) increase [91,92].
A recent paper by Parmar et al. [93] reported an increase
n use of cross sectional imaging, such as CT and MRI and in
articular PET or PET/CT in asymptomatic patients during
he surveillance period. From this study appears that there
as a significant increase in PET/PET-CT use from 2% to 9%
n a 6-year period and a concomitant decrease in bone scan
rom 21% to 13% in the same period. The rise in PET use
nd attendant decrease in bone scan implicates a population
eceiving PET scan in lieu of bone scan for surveillance of
symptomatic metastatic disease. Compared to conventional
maging, FDG PET has been shown to be more sensitive and
pecific in detecting distant metastatic disease [94]. Most data
re derived from the assessment of patients with suspected
ecurrent or metastatic disease comparing FDG PET with
onventional imaging [95–99], although only one study has
ncluded asymptomatic patients as well [97]. On the other
and, asymptomatic tumor marker increase was correlated
ith an elevated sensitivity for the detection of metastases
y PET or PET/CT also in comparison with conventional
maging modalities [100].
As recently reported by Groheux et al. [101], the aggres-
iveness of BC, based on histological features, is directly
orrelated with the glucose metabolism. Triple negative
umors and non-differentiated cancer (Grade 3) demonstrated
 higher uptake of FDG at PET/CT than the other histological
ype and features.
Isasi et al. [102] performed a meta-analysis to assess FDG-
ET for the evaluation of BC recurrences and metastases
nd reported these results: the sensitivity and specificity were
pproximately 92% (56–100%) and 82% (0–100%), respec-
ively.
All studies comparing the diagnostic accuracy of PET with
ET/CT, consistently showed that PET/CT have improved
ensitivity compared with PET but not significant differences
n specificity. In these studies, PET/CT was used for the diag-
osis of local disease and metastases in different locations
nd the advantage of PET/CT over PET appears to be true
hen considered for the detection of disease over a range of
ocations.
Several studies investigated the diagnostic accuracy of
ITs compared with PET or PET/CT on a patient basis
78,97,103–108]; in 2010 Pennant and Colleagues give
ooled summary estimates related with the two diagnostic
trategies: PET had significantly higher sensitivity [89%,
5% confidence interval (CI) 83%–93% vs 79%, 95% CI
2%–85%, relative sensitivity 1.12, 95% CI 1.04–1.21,
m
o
t
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 = 0.005] and significantly higher specificity (93%, 95% CI
3% to 97% vs 83%, 95% CI 67%–92%, relative specificity
.12, 95% CI 1.01–1.24, p = 0.036) [75].
For bone involvement this gain in diagnostic accuracy
btained with PET is controversial and certainly less evident.
n 2011, Houssami and Costelloe [86] reported a system-
tic review that updates the evidence on comparative test
ccuracy for imaging of bone involvement in women with
C; the median sensitivity (based on seven studies) for PET
as 84% (range 77.7%–95.2%), and for bone scan, it was
0% (67.0%–93.3%). The median specificity (seven studies)
or PET was 92% (88.2%–99.0%) and for bone scan 82.4%
9.1%–99.0%).
Overall, PET and PET/CT appear to give improved diag-
ostic accuracy compared with CIT and in the patient-based
nalysis, absolute estimates of sensitivity and specificity were
round 10% higher for PET compared with CIT. Despite this,
he impact of these results on patient management is uncer-
ain. Individual studies emphasize that these technologies do
ead to changes in management, but it is difficult to deter-
ine to what extent these changes would have taken place
ith CITs and, more significantly, whether they modified
nal patient outcome.
Furthermore there are two important limitations of PET
nd PET/CT: economic cost, and biological cost.
In Europe, a PET and a PET/CT scan range between
pproximately D  600 ($885) and D  1000 ($1474), and
eimbursement for these examinations varies significantly
epending on the respective health care systems [109].
With regards to biological costs, Huang et al. [110] calcu-
ated that the effective dose from FDG PET/CT scanning with
 diagnostic CT protocol and an administered FDG activ-
ty of 370 MBq was up to 32.18 mSv, although the standard
mployed PET or PET/CT protocol registered an effective
ose ranged between 6.24 and 9.38 (low dose CT scan and
ess FDG administered activity). Moreover, Chinese authors
eported that the associated lifetime cancer incidence associ-
ted with this dose was estimated to be up to 0.5–14% only
or the U.S. population [111].
. Biomarkers  for  disease  relapse
Since oligometastatic patients have the highest probability
o be long-survivor after a multimodality treatment, the early
ecognition of minimal residual disease should be one of the
ajor goals of BC survivors follow-up.
Depending on the BC subtype, the vast majority of dis-
ase recurrences occur within the first 3–5 years after primary
reatment [30]. Nevertheless, more than one-half of all recurr-
nces and deaths in women with HR-positive disease occur
eyond 5 years from diagnosis [30]. Prognostic biomarkers
ay allow us to assess the natural history and prognosis
f a tumor as well as its potential malignancy over the
ime. Considering that a good prognostic biomarker should
ave a high specificity for a given type of tumor and an
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ppropriate level of sensitivity [112], it is not easy to identify
he perfect biomarker for BC relapse. However, a number of
ifferent prognostic biomarkers have been evaluated over the
ast years.
Mutations within the genes whose products participate in
NA repair, such as BRCA1, BRCA2, and P53, predispose
he patients to an increased risk of developing BC [113,114].
n particular, it has been demonstrated that p53 accumula-
ion is a strong predictor of both early and late recurrence in
R-positive BC patients treated with aromatase inhibitors as
djuvant endocrine therapy [113]. Therefore, patients with
utations identified within the mentioned genes might be
onsidered for a personalized follow-up strategy.
Circulating tumor cells (CTCs) in peripheral blood of
atients with early BC have been shown to be an inde-
endent prognostic factor for disease recurrence and death
115]. A recent study provided evidence of a strong corre-
ation between detection of CTCs during the first five years
f follow-up and increased risk of late disease relapse and
eath in patients early BC, regardless from HR status [116].
oreover, the Authors suggested that the presence of CTCs
ay indicate chemo- and hormonotherapy-resistance in the
icroscopic residual disease after primary treatment. These
ndings may support the role of CTCs monitoring as an
djunct to standard follow-up strategy.
As already mentioned, five different BC subtypes could
e detected by IHC and used as a driver for daily clinical
ractice. However, gene expression analyses may permit a
ore accurate stratification of patients with more aggressive
orms of BC. For example, the MammaPrint Symphony is
 70-gene panel that allowed the stratification of patients
nto groups of high and low risk of relapse [117]. Similarly,
he Oncotype DX is a 21-gene panel developed to assess
he probability of relapse of BC within 10 years by the
nalysis of genes involved in proliferation and invasiveness
118]. Over the years, a number of new gene signatures have
een developed and several comparisons between different
anel and technique have been published [119–121]. Having
 genetic fingerprint of the tumor could be an optimal
olution to drive a more aggressive follow-up strategy, but
he available data are still inhomogeneous and the best panel
as not been identified yet.
MicroRNAs (miRNAs) are a class of small (18–22
ucleotides in length), non-coding RNAs that regulate gene
xpression on a post-transcriptional level [122]. The iden-
ification of a pattern of miRNAs deregulation in BC tissue
ompared with normal breast tissue was first reported in 2005
123]. Since then, several studies have been focused on the
xpression of various miRNAs and their roles in BC devel-
pment and behavior. The analysis of circulating miRNAs
ight provide additional individualized information on prog-
osis and metastatic potential of BC in each patient at the
ime of primary diagnosis. Several different panel of miRNAs
ave been evaluated and an association with both disease-
ree and overall survival has been reported in many cases
124,125], however no validate signature is available yet and
u
e
d
cgy/Hematology 91 (2014) 130–141
he implementation of miRNAs in a follow-up strategy should
e further investigated.
.  Rationale  to  design  new  studies
Surveillance of BC patients with annual mammography
nd clinical examination is the current standard of care. Over
he last few decades, randomized clinical trials have failed to
emonstrate a real benefit of an intensive follow-up strategy.
n contrast with patients and physicians perceptions, literature
ata do not support the introduction of regular blood tests,
umor markers, CT scan, bone scan and other imaging in
he surveillance setting. In addition, the abuse of these tools
n clinical practice could increase anxiety related to false-
ositive results and unnecessary expenses.
However, there could be settings in which an instrumental,
ggressive follow-up schedule could anticipate the diagnosis
f relapse and improve treatment outcomes.
The first possible application of an intensive follow-up
rogram is the MRI surveillance of locoregional recurrence
f young and BRCA positive women. As already described, a
ombined local and systemic treatment can offer real advan-
ages to patients with locoregional relapse. A second field of
nterest is the search of early systemic relapse in patients
ith HER2 positive tumors. The recent improvement in
creening techniques, combined with the availability of active
argeted therapy, may lead to an effective “rescue” treatment
n patients with early detection of tumor relapse. Moreover,
he increased knowledge in breast cancer biology suggests the
eed of a subtype-tailored surveillance strategy, focused on
he different patterns of relapse intrinsic in every breast can-
er molecular subtype. HER2 positive breast cancers seem
articularly suitable for an intensive surveillance of distant
ecurrence: treatment anticipation has shown to confer a sig-
ificant survival advantage. For testing these hypotheses a
ew prospective clinical trial should be designed in which
onventional surveillance strategy is compared with a CT-
ET-based strategy. A further scientific need is the search for
iagnostic tools able to anticipate the radiological evidence
f recurrence: serum markers and circulating tumor cells are
romising and deserve strong investment.
While diagnostic tests in the asymptomatic patients do not
onfer any benefit, a rapid instrumental assessment must be
ctivated in case of clinical suspect of relapse. Unfortunately
hese clinical signs are not often straightforward and their
resence is usually underestimated both by the patients
nd by the physicians. Bone pain, nodal lumps, fatigue,
nintentional weight loss, bowel dysfunction and dyspnea
re example of signs or symptoms whose occurrence should
e carefully evaluated in the clinical context and prompt
n immediate search of disease recurrence. This process is
sually ill-defined and influenced by the subjective skills and
xpertise of the physician, by the strength of the
octor–patient relationship and by the level of recipro-
al trust. The comparative effectiveness of a high-quality,
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tandardized, symptom-driven diagnostic assessment with
he screening of asymptomatic women is another unanswered
uestion.
.  Conclusions
Outside from the experimental setting there is currently no
eason to perform any examination in asymptomatic patients
ther than annual mammography: no single imaging modal-
ty has the required characteristics of sensitivity, specificity
nd cost-effectiveness ratio to be considered suitable for BC
ollow-up. Intensive surveillance is associated with false-
ositive findings, induction of anxiety, risk of exposure to
adiation, and unjustified costs. Information of patients and
ducation of physicians should be pursued. However, the bio-
ogical knowledge and the management improvement should
e considered the basis for a renewed interest of research
n the field of follow-up. Are probably definitively gone the
imes of a “one size fits all” strategy: BC is a heterogeneous
isease and different approaches should be adapted to the dif-
erent disease subtypes. The combination of the best current
iagnostic tools with the best therapies may demonstrate that
he anticipation of relapse detection and treatment is worth
f value in specific settings. This research is eagerly awaited.
onﬂict  of  interest
The authors declare no conflict of interest.
uthors’  contributions
All authors drafted, read and approved the final version of
he manuscript.
eviewers
Javier Cortès, M.D. Ph.D., Hospital Valle Hebron, Oncol-
gy Department, Barcelona, Spain.
Christoph C. Zielinski, Professor, M.D., Chairman, Med-
cal University of Vienna, Department of Medicine I,
aehringer Guertel 18-20, A-1090 Vienna, Austria.
Natalie Turner, MBBS, Prato Hospital, Via Ugo Foscolo,
-59100 Prato, Italy.
cknowledgements
This review is part of a special project of the AIOM (Asso-
iazione Italiana di Oncologia Medica) working group on
ollow-up of breast cancer.gy/Hematology 91 (2014) 130–141 137
eferences
[1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer
J Clin 2013;63(1):11–30.
[2] Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N
Engl J Med 2000;343(15):1086–94.
[3] Rojas MP, Telaro E, Moschetti I, et al. Follow-up strategies for
women treated for early breast cancer. Cochrane Database Syst Rev
2009;25(1):CD001768 [review].
[4] Koch L, Jansen L, Herrmann A, et al. Quality of life in long-term
breast cancer survivors – a 10-year longitudinal population-based
study. Acta Oncol 2013;52(6):1119–28.
[5] Jacobs HJ, van Dijck JA, de Kleijn EM, Kiemeney LA, Verbeek
AL. Routine follow-up examinations in breast cancer patients have
minimal impact on life expectancy: a simulation study. Ann Oncol
2001;12(8):1107–13.
[6] The GIVIO Investigators. Impact of follow-up testing on survival and
health-related quality of life in breast cancer patients. A multicenter
randomized controlled trial. JAMA 1994;271(20):1587–92.
[7] Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P,
Distante V. Intensive diagnostic follow-up after treatment of pri-
mary breast cancer. A randomized trial, National Research Council
Project on Breast Cancer follow-up. JAMA 1994;271((20) May):
1593–7.
[8] Palli D, Russo A, Saieva C, et al. Intensive vs clinical follow-up after
treatment of primary breast cancer: 10-year update of a randomized
trial. National Research Council Project on Breast Cancer Follow-up.
JAMA 1999;281(17):1586.
[9] Gulliford T, Opomu M, Wilson E, Hanham I, Epstein R. Popularity of
less frequent follow up for breast cancer in randomised study: initial
findings from the hotline study. BMJ 1997;314(7075):174–7.
[10] Grunfeld E, Mant D, Yudkin P, et al. Routine follow up of breast cancer
in primary care: randomized trial. BMJ 1996;313(7058):665–9.
[11] Grunfeld E, Levine MN, Julian JA, et al. Randomized trial of long-
term follow-up for early-stage breast cancer: a comparison of family
physician versus specialist care. J Clin Oncol 2006;24(6):848–55.
[12] Khatcheressian JL, Hurley P, Bantug E, et al. Breast cancer follow-
up and management after primary treatment: American Society of
Clinical Oncology clinical practice guideline update. J Clin Oncol
2013;31(7):961–5.
[13] Hayes DF. Clinical practice. Follow-up of patients with early breast
cancer. N Engl J Med 2007;356(24):2505–13.
[14] NCCN Guidelines: Breast Cancer Version 3. http://www.nccn.org/
professionals/physician gls/pdf/breast.pdf; 2013; [accessed
27.01.14].
[15] Aebi S, Davidson T, Gruber G, Cardoso F. Primary breast can-
cer: ESMO clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol 2011;22(Suppl. 6):vi12–24.
[16] Mille D, Roy T, Carrère MO, et al. Economic impact of harmonizing
medical practices: compliance with clinical practice guidelines in the
follow-up of breast cancer in a French Comprehensive Cancer Center.
J Clin Oncol 2000;18(8):1718–24.
[17] Potosky AL, Han PK, Rowland J, et al. Differences between pri-
mary care physicians’ and oncologists’ knowledge, attitudes and
practices regarding the care of cancer survivors. J Gen Intern Med
2011;26(12):1403–10.
[18] Schnipper LE, Smith TJ, Raghavan D, et al. American Society
of Clinical Oncology identifies five key opportunities to improve
care and reduce costs: the top five list for oncology. J Clin Oncol
2012;30(14):1715–24.
[19] Grunfeld E, Hodgson DC, Del Giudice ME, Moineddin R. Population-
based longitudinal study of follow-up care for breast cancer survivors.
J Oncol Pract 2010;6(4):174–81.Surveillance testing among survivors of early-stage breast cancer. J
Clin Oncol 2007;25(9):1074–81.
1  Oncolo38 F. Puglisi et al. / Critical Reviews in
[21] Numico G, Pinto C, Ucci G, et al. How are cared surviving cancer
patients? Results of an Italian national survey to medical oncologists
(MO) about clinical and organizational features of follow-up (FU). J
Clin Oncol (Proc ASCO Annu Meet) 2012;30(15 Suppl.):e19592.
[22] Mayer EL, Gropper AB, Neville BA, et al. Breast cancer sur-
vivors’ perceptions of survivorship care options. J Clin Oncol
2012;30(2):158–63.
[23] Earle CC. Failing to plan is planning to fail: improving the quality of
care with survivorship care plans. J Clin Oncol 2006;24(32):5112–6.
[24] Grunfeld E, Moineddin R, Gunraj N, et al. Cancer screening practices
of cancer survivors: population-based, longitudinal study. Can Fam
Physician 2012;58(9):980–6.
[25] Jatoi I, Anderson WF, Jeong JH, Redmond CK. Breast cancer
adjuvant therapy: time to consider its time-dependent effects. J
Clin Oncol 2011;29((17) June):2301–4 [erratum in: J Clin Oncol
2010;29(29);3948].
[26] Guiu S, Michiels S, André F, et al. Molecular subclasses of breast
cancer: how do we define them? The IMPAKT 2012 Working Group
Statement. Ann Oncol 2012;23(12):2997–3006.
[27] Cianfrocca M, Gradishar W. New molecular classifications of breast
cancer. CA Cancer J Clin 2009;59(5):303–13.
[28] Goldhirsch A, Winer EP, Coates AS, et al. Panel members. Personal-
izing the treatment of women with early breast cancer: highlights
of the St Gallen International Expert Consensus on the Primary
Therapy of Early Breast Cancer 2013. Ann Oncol 2013;24(9):
2206–23.
[29] Metzger-Filho O, Sun Z, Viale G, et al. Patterns of Recurrence and
outcome according to breast cancer subtypes in lymph node-negative
disease: results from international breast cancer study group trials
VIII and IX. J Clin Oncol 2013;31((25) September):3083–90.
[30] Jatoi I, Anderson WF, Jeong JH, Redmond CK. Breast cancer adjuvant
therapy: time to consider its time-dependent effects. J Clin Oncol
2011;29(17):2301–4.
[31] Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics
review, 1975–2001. Bethesda, MD: National Cancer Institute; 2004
http://seer.cancer.gov/csr/1975 2001/
[32] Waeber M, Castiglione-Gertsch M, Dietrich D, et al. Adjuvant therapy
after excision and radiation of isolated postmastectomy locoregional
breast cancer recurrence: definitive results of a phase III random-
ized trial (SAKK 23/82) comparing tamoxifen with observation. Ann
Oncol 2003;14((8) August):1215–21.
[33] Aebi S, Gelber S, Lang I, et al. Chemotherapy prolongs survival for
isolated local or regional recurrence of breast cancer: the CALOR trial
(chemotherapy as adjuvant for locally recurrent breast cancer; IBCSG
27-02, NSABP B-37, BIG 1-02). Cancer Res 2012;72(24 Suppl.):96s
[abstract S3-2].
[34] Elder EE, Kennedy CW, Gluch L, et al. Patterns of breast cancer
relapse. Eur J Surg Oncol 2006;32(9):922–7.
[35] Saigal K, Hurley J, Takita C, et al. Risk factors for locoregional failure
in patients with inflammatory breast cancer treated with trimodality
therapy. Clin Breast Cancer 2013;13(5):335–43.
[36] Yadav BS, Sharma SC, Singh R, Singh G. Patterns of relapse in locally
advanced breast cancer treated with neoadjuvant chemotherapy fol-
lowed by surgery and radiotherapy. J Cancer Res Ther 2007;3((2)
April–June):75–80.
[37] Lu WL, Jansen L, Post WJ, Bonnema J, Van de Velde JC, De Bock GH.
Impact on survival of early detection of isolated breast recurrences
after the primary treatment for breast cancer: a meta-analysis. Breast
Cancer Res Treat 2009;114(3):403–12.
[38] Stomper PC, Winston JS, Herman S, Klippenstein DL, Arredondo
MA, Blumenson LE. Angiogenesis and dynamic MR imaging
gadolinium enhancement of malignant and benign breast lesions.
Breast Cancer Res Treat 1997;45(1):39–46.[39] Dershaw DD, McCormick B, Osborne MP. Detection of local
recurrence after conservative therapy for breast carcinoma. Cancer
1992;70(2):493–6.gy/Hematology 91 (2014) 130–141
[40] Orel SG, Troupin RH, Patterson EA, Fowble BL. Breast cancer recur-
rence after lumpectomy and irradiation: role of mammography in
detection. Radiology 1992;183(1):201–6.
[41] Winehouse J, Douek M, Holz K, et al. Contrast-enhanced colour
Doppler ultrasonography in suspected breast cancer recurrence. Br
J Surg 1999;86(9):1198–201.
[42] Hagay C, Cherel PJ, de Maulmont CE, et al. Contrast-enhanced CT:
value for diagnosing local breast cancer recurrence after conservative
treatment. Radiology 1996;200(3):631–8.
[43] Belli P, Costantini M, Romani M, Marano P, Pastore G. Magnetic
resonance imaging in breast cancer recurrence. Breast Cancer Res
Treat 2002;73(3):223–35.
[44] Orel SG, Schnall MD. MR imaging of the breast for the
detection, diagnosis, and staging of breast cancer. Radiology
2001;220(1):13–30.
[45] Pan L, Han Y, Sun X, Liu J, Gang H. FDG-PET and other
imaging modalities for the evaluation of breast cancer recur-
rence and metastases: a meta-analysis. J Cancer Res Clin Oncol
2010;136(7):1007–22.
[46] Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and
mammography for breast-cancer screening in women with a familial
or genetic predisposition. N Engl J Med 2004;351(5):427–37.
[47] Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic
resonance imaging and mammography of a UK population at high
familial risk of breast cancer: a prospective multicentre cohort study
(MARIBS). Lancet 2005;365(9473):1769–78.
[48] Lehman CD, Blume JD, Weatherall P, et al. Screening women at high
risk for breast cancer with mammography and magnetic resonance
imaging. Cancer 2005;103(9):1898–905.
[49] Menell JH, Morris EA, Dershaw DD, Abramson AF, Brogi E, Liber-
man L. Determination of the presence and extent of pure ductal
carcinoma in situ by mammography and magnetic resonance imaging.
Breast J 2005;11(6):382–90.
[50] Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1
and BRCA2 mutation carriers with magnetic resonance imaging,
ultrasound, mammography, and clinical breast examination. JAMA
2004;292(11):1317–25.
[51] Houssami N, Hayes DF. Review of preoperative magnetic resonance
imaging (MRI) in breast cancer: should MRI be performed on all
women with newly diagnosed, early stage breast cancer? CA Cancer
J Clin 2009;59(5):290–302.
[52] Mumtaz H, Davidson T, Hall-Craggs MA, et al. Comparison of mag-
netic resonance imaging and conventional triple assessment in locally
recurrent breast cancer. Br J Surg 1997;84((8) August):1147–51.
[53] Friedrich M. MRI of the breast: state of the art. Eur Radiol
1998;8(5):707–25.
[54] Krämer S, Schulz-Wendtland R, Hagedorn K, Bautz W, Lang N. Mag-
netic resonance imaging in the diagnosis of local recurrences in breast
cancer. Anticancer Res 1998;18(3 C):2159–61.
[55] Rieber A, Merkle E, Zeitler H, et al. Value of MR mammography in
the detection and exclusion of recurrent breast carcinoma. J Comput
Assist Tomogr 1997;21(5):780–4.
[56] Gilles R, Guinebretière JM, Shapeero LG, et al. Assessment of breast
cancer recurrence with contrast-enhanced subtraction MR imaging:
preliminary results in 26 patients. Radiology 1993;188(2):473–8.
[57] Dao TH, Rahmouni A, Campana F, Laurent M, Asselain B, Fourquet
A. Tumor recurrence versus fibrosis in the irradiated breast: differen-
tiation with dynamic gadolinium-enhanced MR imaging. Radiology
1993;187(3):751–5.
[58] Hathaway PB, Mankoff DA, Maravilla KR, et al. Value of combined
FDG PET and MR imaging in the evaluation of suspected recur-
rent local-regional breast cancer: preliminary experience. Radiology
1999;210(3):807–14.[59] Panageas KS, Sima CS, Liberman L, Schrag D. Use of high tech-
nology imaging for surveillance of early stage breast cancer. Breast
Cancer Res Treat 2012;131(2):663–70.
 OncoloF. Puglisi et al. / Critical Reviews in
[60] Houssami N, Turner R, Macaskill P, et al. An individual person data
meta-analysis of preoperative magnetic resonance imaging and breast
cancer recurrence. J Clin Oncol 2014;32(5):392–401.
[61] Hortobagyi GN. Can we cure limited metastatic breast cancer? J Clin
Oncol 2002;20(3):620–3.
[62] Kobayashi T, Ichiba T, Sakuyama T, et al. Possible clinical cure of
metastatic breast cancer: lessons from our 30-year experience with
oligometastatic breast cancer patients and literature review. Breast
Cancer 2012;19(3):218–37.
[63] Tomiak E, Piccart M, Mignolet F, et al. Characterisation of com-
plete responders to combination chemotherapy for advanced breast
cancer: a retrospective EORTC Breast Group study. Eur J Cancer
1996;32A(11):1876–87.
[64] Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK,
Buzdar AU. Long-term follow-up of patients with complete remission
following combination chemotherapy for metastatic breast cancer. J
Clin Oncol 1996;14(8):2197–205.
[65] Singletary SE, Walsh G, Vauthey JN, et al. A role for curative surgery
in the treatment of selected patients with metastatic breast cancer.
Oncologist 2003;8(3):241–51.
[66] Girard P, Baldeyrou P, Le Chevalier T, et al. Surgery for pulmonary
metastases. Who are the 10-year survivors? Cancer 1994;74((10)
November):2791–7. PubMed PMID: 7954238.
[67] McKenna Jr RJ, McMurtrey MJ, Larson DL, Mountain CF. A per-
spective on chest wall resection in patients with breast cancer. Ann
Thorac Surg 1984;38(5):482–7.
[68] Temple WJ, Ketcham AS. Surgical management of isolated systemic
metastases. Semin Oncol 1980;7(4):468–80.
[69] Holmes FA, Buzdar AU, Kau S-W, et al. Combined-modality
approach for patients with isolated recurrences of breast cancer (IV-
NED): The M.D. Anderson experience. Breast Dis 1994;7:7–20.
[70] Berman AT, Thukral AD, Hwang WT, Solin LJ, Vapiwala N. Inci-
dence patterns of distant metastases for patients with early-stage
breast cancer after breast conservation treatment. Clin Breast Cancer
2013;13:88–94.
[71] Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus
a monoclonal antibody against HER2 for metastatic breast cancer that
overexpresses HER2. N Engl J Med 2001;344(11):783–92.
[72] Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH.
Prognosis of women with metastatic breast cancer by HER2 status
and trastuzumab treatment: an institutional-based review. J Clin Oncol
2010;28(1):92–8.
[73] Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab
plus docetaxel for metastatic breast cancer. N Engl J Med
2012;366(2):109–19.
[74] Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and
docetaxel for HER2-positive metastatic breast cancer (CLEOPA-
TRA study): overall survival results from a randomised, double-blind,
placebo-controlled, phase 3 study. Lancet Oncol 2013;14(6):461–71.
[75] Pennant M, Takwoingi Y, Pennant L, et al. A systematic review of
positron emission tomography (PET) and positron emission tomo-
graphy/computed tomography (PET/CT) for the diagnosis of breast
cancer recurrence. Health Technol Assess 2010;14(50):1–103.
[76] Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O. The role
of FDG-PET/CT in suspected recurrence of breast cancer. Cancer
2006;107(11):2545–51.
[77] Ternier F, Houvenaeghel G, Lecrivain F, et al. Computed tomography
in suspected local breast cancer recurrence. Breast Cancer Res Treat
2006;100(3):247–54.
[78] Gallowitsch HJ, Kresnik E, Gasser J, et al. F-18 fluorodeoxyglucose
positron-emission tomography in the diagnosis of tumor recur-
rence and metastases in the follow-up of patients with breast
carcinoma: a comparison to conventional imaging. Invest Radiol
2003;38(5):250–6.[79] Piperkova E, Raphael B, Altinyay ME, et al. Impact of PET/CT in
comparison with same day contrast enhanced CT in breast cancer
management. Clin Nucl Med 2007;32(6):429–34.gy/Hematology 91 (2014) 130–141 139
[80] Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno
NT. Bone imaging in metastatic breast cancer. J Clin Oncol
2004;22(14):2942–53.
[81] Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term pre-
vention of skeletal complications of metastatic breast cancer with
pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin
Oncol 1998;16(6):2038–44.
[82] Rubens RD. Bone metastases—the clinical problem. Eur J Cancer
1998;34(2):210–3.
[83] Matro JM, Goldstein LJ. How do I follow patients with early breast
cancer after completing adjuvant therapy. Curr Treat Options Oncol
2013;15(1):63–78.
[84] Muindi J, Coombes RC, Golding S, Powles TJ, Khan O, Husband J.
The role of computed tomography in the detection of bone metastases
in breast cancer patients. Br J Radiol 1983;56(664):233–6.
[85] Kamholtz R, Sze G. Current imaging in spinal metastatic disease.
Semin Oncol 1991;18(2):158–69.
[86] Houssami N, Costelloe CM. Imaging bone metastases in breast
cancer: evidence on comparative test accuracy. Ann Oncol
2012;23(4):834–43.
[87] Yeh KA, Fortunato L, Ridge JA, Hoffman JP, Eisenberg BL, Sigurdson
ER. Routine bone scanning in patients with T1 and T2 breast cancer:
a waste of money. Ann Surg Oncol 1995;2(4):319–24.
[88] Liu T, Cheng T, Xu W, Yan WL, Liu J, Yang HL. A meta-analysis
of 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone
metastases in patients with breast cancer. Skeletal Radiol 2011;40:
523–31.
[89] Siggelkow W, Zimny M, Faridi A, Petzold K, Buell U, Rath W. The
value of positron emission tomography in the follow-up for breast
cancer. Anticancer Res 2003;23(2C):1859–67.
[90] Peterson JJ, Kransdorf MJ, O‘Connor MI. Diagnosis of occult bone
metastases: positron emission tomography. Clin Orthop Relat Res
2003;(415 Suppl.):S120–8.
[91] Evangelista L, Baretta Z, Vinante L, et al. Could the serial determi-
nation of Ca15.3 serum improve the diagnostic accuracy of PET/CT?
Results from small population with previous breast cancer. Ann Nucl
Med 2011;25:469–77.
[92] Evangelista L, Cervino AR, Ghiotto C, Al-Nahhas A, Rubello D,
Muzzio PC. Tumor marker-guided PET in breast cancer patients-a
recipe for a perfect wedding: a systematic literature review and meta-
analysis. Clin Nucl Med 2012;37:467–74.
[93] Parmar AD, Sheffield KM, Vargas GM, Han Y, Chao C, Riall TS.
Quality of post-treatment surveillance of early stage breast cancer in
Texas. Surgery 2013;154:214–25.
[94] Constantinidou A, Martin A, Sharma B, Johnston SR. Positron
emission tomography/computed tomography in the management of
recurrent/metastatic breast cancer: a large retrospective study from
the Royal Marsden Hospital. Ann Oncol 2011;22:307–14.
[95] Dose J, Bleckmann C, Bachmann S, et al. Comparison of fluo-
rodeoxyglucose positron emission tomography and “conventional
diagnostic procedures” for the detection of distant metastases in breast
cancer patients. Nucl Med Commun 2002;23(9):857–64.
[96] Gallowitsch HJ, Kresnik E, Gasser J, et al. F-18 fluorodeoxyglucose
positron-emission tomography in the diagnosis of tumor recurrence
and metastases in the follow-up of patients with breast carcinoma: a
comparison to conventional imaging. Invest Radiol 2003;38:250–6.
[97] Siggelkow W, Zimny M, Faridi A, Petzold K, Buell U, Rath W. The
value of positron emission tomography in the follow-up for breast
cancer. Anticancer Res 2003;23:1859–67.
[98] Eubank WB, Mankoff D, Bhattacharya M, et al. Impact of FDG PET
on defining the extent of disease and on the treatment of patients
with recurrent or metastatic breast cancer. AJR Am J Roentgenol
2004;183:479–86.
[99] Santiago JF, Gonen M, Yeung H, Macapinlac H, Larson S. A ret-
rospective analysis of the impact of 18F-FDG PET scans on clinical
management of 133 breast cancer patients. Q J Nucl Med Mol Imaging
2006;50:61–7.
1  Oncolo
B
M
s
v
h
U
o
e
o
p
B
d
n
o
s
H
2
F
o
T
G
t
n
O40 F. Puglisi et al. / Critical Reviews in
[100] Liu CS, Shen YY, Lin CC, Yen RF, Kao CH. Clinical impact of
[(18)F]FDG-PET in patients with suspected recurrent breast cancer
based on asymptomatically elevated tumor marker serum levels: a
preliminary report. Jpn J Clin Oncol 2002;32(7):244–7.
[101] Groheux D, Giacchetti S, Moretti JL, et al. Correlation of high 18F-
FDG uptake to clinical, pathological and biological prognostic factors
in breast cancer. Eur J Nucl Med Mol Imaging 2011;38(3):426–35.
[102] Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET
for the evaluation of breast cancer recurrence and metastases. Breast
Cancer Res Treat 2005;90(2):105–12.
[103] Abe K, Sasaki M, Kuwabara Y, et al. Comparison of 18FDG-PET with
99mTc-HMDP scintigraphy for the detection of bone metastases in
patients with breast cancer. Ann Nucl Med 2005;19(7):573–9.
[104] Ohta M, Tokuda Y, Suzuki Y, et al. Whole body PET for the
evaluation of bony metastases in patients with breast cancer: com-
parison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun
2001;22(8):875–9.
[105] Dirisamer A, Halpern BS, Flöry D, et al. Integrated contrast-enhanced
diagnostic whole-body PET/CT as a first-line restaging modality in
patients with suspected metastatic recurrence of breast cancer. Eur J
Radiol 2010;73(2):294–9.
[106] Haug AR, Schmidt GP, Klingenstein A, et al. F-18-fluoro-2-
deoxyglucose positron emission tomography/computed tomography
in the follow-up of breast cancer with elevated levels of tumor markers.
J Comput Assist Tomogr 2007;31(4):629–34.
[107] Vranjesevic D, Filmont JE, Meta J, et al. Whole-body (18)F-FDG
PET and conventional imaging for predicting outcome in previously
treated breast cancer patients. J Nucl Med 2002;43(3):325–9.
[108] Wolfort RM, Li BD, Johnson LW, et al. The role of whole-body
fluorine-18-FDG positron emission tomography in the detection of
recurrence in symptomatic patients with stages II and III breast cancer.
World J Surg 2006;30(8):1422–7.
[109] Buck AK, Herrmann K, Stargardt T, Dechow T, Krause BJ, Schreyögg
J. Economic evaluation of PET and PET/CT in oncology: evidence
and methodologic approaches. J Nucl Med Technol 2010;38(1):6–17.
[110] Huang B, Law MW, Khong PL. Whole-body PET/CT scan-
ning: estimation of radiation dose and cancer risk. Radiology
2009;251(1):166–74.
[111] Ghotbi N, Iwanaga M, Ohtsuru A, Ogawa Y, Yamashita S. Cancer
screening with whole-body PET/CT for healthy asymptomatic people
in Japan: re-evaluation of its test validity and radiation exposure. Asian
Pac J Cancer Prev 2007;8(1):93–7.
[112] Bates SE. Clinical applications of serum tumor markers. Adv Intern
Med 1991;115(8):623–38.
[113] Narod SA. BRCA mutations in the management of breast cancer: the
state of the art. Nat Rev Clin Oncol 2010;7(12):702–7.
[114] Yamamoto M, Hosoda M, Nakano K, et al. p53 accumulation is a
strong predictor of recurrence in estrogen receptor-positive breast
cancer patients treated with aromatase inhibitors. Cancer Sci 2013,
http://dx.doi.org/10.1111/cas.12302 [Epub ahead of print].
[115] Stathopoulou A, Vlachonikolis I, Mavroudis D, et al. Molecular detec-
tion of cytokeratin-19-positive cells in the peripheral blood of patients
with operable breast cancer: evaluation of their prognostic signifi-
cance. J Clin Oncol 2002;20(16):3404–12.
[116] Saloustros E, Perraki M, Apostolaki S, et al. Cytokeratin-19 mRNA-
positive circulating tumor cells during follow-up of patients with
operable breast cancer: prognostic relevance for late relapse. Breast
Cancer Res 2011;13(3):R60.
[117] Bueno-de-Mesquita JM, Linn SC, Keijzer R, et al. Validation of
70-gene prognosis signature in node-negative breast cancer. Breast
Cancer Res Treat 2009;117(3):483–95.
[118] Carlson JJ, Roth JA. The impact of the Oncotype Dx breast can-
cer assay in clinical practice: a systematic review and meta-analysis.
Breast Cancer Res Treat 2013;141(1):13–22.
[119] Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of
PAM50 risk of recurrence score with oncotype DX and IHC4 for
o
t
ogy/Hematology 91 (2014) 130–141
predicting risk of distant recurrence after endocrine therapy. J Clin
Oncol 2013;31(22):2783–90.
[120] Varga Z, Sinn P, Fritzsche F, et al. Comparison of EndoPredict and
Oncotype DX test results in hormone receptor positive invasive breast
cancer. PLoS ONE 2013;8(3):e58483.
[121] Naoi Y, Kishi K, Tsunashima R, et al. Comparison of efficacy of
95-gene and 21-gene classifier (Oncotype DX) for prediction of recur-
rence in ER-positive and node-negative breast cancer patients. Breast
Cancer Res Treat 2013;140(2):299–306.
[122] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and func-
tion. Cell 2004;116(2):281–97.
[123] Corcoran C, Friel AM, Duffy MJ, Crown J, O’Driscoll L. Intra-
cellular and extracellular microRNAs in breast cancer. Clin Chem
2011;57:18–32.
[124] Markou A, Yousef GM, Stathopoulos E, Georgoulias V, Lian-
idou E. Prognostic significance of metastasis-related MicroRNAs
in early breast cancer patients with a long follow-up. Clin Chem
2014;60(1):197–205.
[125] Cuk K, Zucknick M, Madhavan D, et al. Plasma microRNA panel
for minimally invasive detection of breast cancer. PLoS ONE
2013;8(10):e76729.
[126] Linee guida AIOM -Associazione Italiana di Oncologia Medica-
http://www.aiom.it/area+pubblica/area+medica/prodotti+scientifici/
linee+guida/1,333,1
iographies
Fabio  Puglisi  (MD, PhD) is researcher and professor of
edical Oncology at the University of Udine, Italy and senior
taff member of the Department of Medical Oncology, Uni-
ersity Hospital of Udine, Italy. Since 1998, prof. Puglisi
as held his teaching activity mainly for the University of
dine, Italy and in regional and national courses. He is author
f several publications in scientific peer-reviewed journals,
specially in his main fields of interest (i.e. clinical trials
n breast cancer treatment and research on prognostic and
redictive factors). He is an active member of International
reast Cancer Study Group (IBCSG), Michelangelo Foun-
ation, Gruppo Italiano Mammella (GIM). Puglisi is also
ational treasurer of Italian Association of Medical Oncol-
gy (AIOM). As an expert on clinical trials in oncology, he
erved on the Board of the Ethical Committee of the General
ospital of Trieste, Italy.
Caterina  Fontanella  received her Medical Degree in
010 from the University of Trieste, Italy. Since 2011, Dr.
ontanella works as postgraduate student at the Department
f Medical Oncology, University Hospital of Udine, Italy.
o date, she is a fellowship researcher at the German Breast
roup institute in Neu-Isenburg, Germany. Dr. Fontanella is
he co-author of different publications in peer-reviewed jour-
als and she is a member of Italian Association of Medical
ncology (AIOM).
Gianmauro  Numico  is Head of the Medical Oncology Unitf the “Azienda USL della Valle d’Aost”, Aosta, Italy. He is
he coordinator of the working group on cancer follow up
f the Italian Association of Medical Oncology (AIOM) and
 Oncolo
i
g
i
“
c
S
g
i
P
a
“
d
j
b
g
i
c
F
“
l
2
Y
o
o
–
a
n
m
t
H
B
C
t
R
T
m
o
o
C
s
o
s
c
i
b
A
S
S
o
j
a
t
s
I
G
t
c
i
s
c
r
E
c
o
s
IF. Puglisi et al. / Critical Reviews in
s the reference in the Piemonte and Valle d’Aosta Oncolo-
ical network. Survivorship care is one of his main field of
nterest.
Valentina  Sini  received her Medical Degree in 2006 from
Tor Vergata” University of Rome, Italy. In 2011 she spe-
ialized in Oncology, “Tor Vergata” University of Rome.
ince 2011 she is a PhDs in PhD University Grant Pro-
ram “Clinical and Experimental Research Methodologies
n Oncology” provided by the Faculty of Medicine and
sychology, “Sapienza” University of Rome. She is an
ssistant at the Oncology Unit, Department of Oncology
Sant’Andrea” Hospital of Rome. She authored/coauthored
ifferent papers published in peer-reviewed international
ournals. Current areas of research include new treatments of
reast cancer, cardiac and endocrine-related toxicity of tar-
eted and cytotoxic agents, optimization of endocrine therapy
n breast cancer.
Laura Evangelista, MD PhD, is a nuclear medicine physi-
ian at Istituto Oncologico Veneto IOV–IRCCS Padova, Italy.
ollowing her residency in Nuclear Medicine at University
Federico II” of Napoli Italy, she worked as research fel-
ow at University “Federico II” of Napoli Italy (from January
009 to June 2009) and Memorial Sloan Kettering of New
ork City, USA (from January 2011 to April 2011) focusing
n PET/CT in breast cancer and molecular imaging. More-
ver, in 2009 she moved at Istituto Oncologico Veneto IOV
 IRCCS Padova, Italy, where she is currently working as
 nuclear medicine physician, with a special interest in the
uclear diagnostic evaluation of breast cancer.
Francesco  Monetti  received his M.D. degree with full
arks from the University of Genoa, Italy in 1996. He took
he specialty in Radiology in 2000 at the University of Genoa.
e worked as radiologist in the Department of Radiology,
reast Imaging Section, San Martino Hospital - IST-National
ancer Institute, Genoa since 2001 until now. He is also
he Quality Manager of the department since 2011. He was
adiology Reviewer for EORTC in EORTC phase II study:
p
s
mgy/Hematology 91 (2014) 130–141 141
he activity of raltitrexed (Tomudex) in malignant pleural
esothelioma. He is OECI auditor since 2013. He is member
f Italian Society of Medical Radiology (S.I.R.M.).
Stefania  Gori  is currently Director of the Medical Oncol-
gy Division in the Department of Oncology at the Sacro
uore – Don Calabria Hospital, Negrar, Verona, Italy. She
pecializes in Internal Medicine and in Medical Oncol-
gy. Stefania Gori’s research interests include experimental
tudies on basic and clinical applied research on breast
ancer. She has been the Principal Investigator of many
ndustry-sponsored clinical trials. Stefania Gori is a mem-
er of numerous scientific societies, including the Italian
ssociation of Medical Oncology (AIOM), the European
ociety of Medical Oncology (ESMO), and the American
ociety of Clinical Oncology (ASCO). She is the author
r co-author of more than 60 publications in peer-reviewed
ournals.
Lucia Del  Mastro  received his M.D. degree with full marks
nd honours from the University of Naples, Italy in 1989. She
ook the specialty in Medical Oncology in 1993 at the Univer-
ity of Naples. She is the director of the S.S. Sviluppo Terapie
nnovative at the IRCCS AOU San Martino-IST Hospital in
enoa, Italy. She is principal investigator of phase II and III
rials in metastatic and early breast cancer patients, and prin-
ipal investigator of toxicity and supportive care studies. She
s reviewer of international papers for many scientific journals
uch as: Annals of Oncology, The Lancet, Journal of Clini-
al Oncology, Cancer Research and The Oncologist. She is
eviewer of research projects for Cancer Research UK and
uropean Organization for Research and Treatmemt of Can-
er (EORTC). She is member of the Scientific Committee
f GIM (Gruppo Italiano Mammella). She is the chairper-
on of the steering committee of the AIOM (Associazione
taliana Oncologia Medica) recommendations for fertility
reservation in cancer patients and she is a member of the
teering committee of the AIOM recommendations for the
anagement of breast cancer patients.
